Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of CES on Emotional and Cellular Wellbeing

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male~2. Within the age range of 18-40 years old~3. Score 8-14 on either the anxiety or depression HADS scale as defined as mild (8-10) to moderate (11-14)~4. Subjects who receive anxiety, depression, psychiatric or mental health treatment (pharmacological or non-pharmacological) must be on a stable regimen for the past 3 months~5. No active suicidal ideation or psychosis (including schizophrenia and bipolar disorder)~6. No uncontrolled or progressive severe medical illness (e.g., cancer, uncontrolled diabetes mellitus, active cardiac disease)~7. No use of a pacemaker or any other implanted electrical device~8. No alcohol consumption greater than 2 units daily~9. Ability to independently complete the in-person study questionnaires and sign informed consent form (ICF) without assistance~10. Willing to comply with all study procedures and be available for the duration of the study~11. No participation in another clinical trial study~Exclusion Criteria:~1. Not a male~2. Younger than 18 years old or older than 40 years old~3. Score ≥15 on either the anxiety or depression HADS scale as defined as severe (15-20)~4. Subject who receive anxiety, depression, psychiatric or mental health treatment (pharmacological or non-pharmacological) who have not been on a stable regimen for the past 3 months~5. Active suicidal ideation or psychosis (including schizophrenia and bipolar disorder)~6. History of inpatient treatment or suicidal ideation within the last year~7. Use of a pacemaker or any other implanted electrical device~8. Unable to independently complete the in-person study questionnaires and sign ICF due to impaired cognitive function~9. Unwilling to comply with all study procedures~10. Unavailable for the duration of the study~11. Current participation in another clinical trial study~12. Any other condition that the investigator believes would jeopardize the safety or rights of the subject or would render the subject unable to comply with the study protocol or make use of acquired data non-analyzable

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- Active (Type: ACTIVE_COMPARATOR): Subjects will be given an Alpha-Stim active device for daily treatment. The electrodes attached to the device will be active. The device frequency is preset to 0.5 Hz and 100 microampere and treatment is one hour daily. The subjects will be instructed that the device is set to a low level so that the current is not detectable but should still be effective. The current will not be detectable in both active and sham devices in order for adequate blinding to occur.
- Inactive (Type: SHAM_COMPARATOR): Subjects will be given an Alpha-Stim inactive device for daily treatment. The electrodes attached to the device will be inactive. The device will not transmit anything when turned on because the electrodes are inactive. The frequency on the device will state 0.5 Hz and 100 microampere but it will not actually emit anything. Subjects in this group will receive treatment one hour daily. The subjects will be instructed that the device is set to a low level so that the current is not detectable but should still be effective. The current will not be detectable in both active and sham devices in order for adequate blinding to occur.

Based on this trial design, predict the completion outcome and termination type (if applicable).